Week in Review: China Healthcare and Pharma Deals

Singapore's Temasek will invest $250 million in a Columbia Pacific Management JV to build China healthcare facilities; Luye Medical offered $91 million to acquire Pulse Medical, an Australian hospital chain; Veritas Genetics, a Boston-Hangzhou affordable genetics testing company, raised $30 million from China-connected investors; Quark Venture and China's GF Securities announced a $500 million global health sciences venture fund; Zai Lab of Shanghai in-licensed global rights to two anti-inflammatory candidates from GlaxoSmithKline; FMD K&L, a US-China clinical CRO, announced plans to merge with iMEDGlobal, a US-India pre-clinical CRO; Shanghai's Hua Medicine announced positive results from a China Phase II trial of its GKA treatment for diabetes; MicuRx Pharma began a pivotal China Phase III trial of its oral antibiotic for drug-resistant infections; TLC, a Taiwan novel drug maker, was granted US Orphan Drug designation for a lymphoma treatment; CStone Pharma of Shanghai and Suzhou said China accepted its IND application for a PD-L1 antibody; and Suzhou's Tot Biopharm broke ground on a biologic production facility. More details.... Stock Symbols: (HK: 2186) (HK: 01776; SHZ: 000776) (NYSE: GSK) (TT: 4152) Share this with colleagues: // //